Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Xiang Zhang,Zi‐Yi Li,Jia‐Heng Xiao,Peng‐Fei Hao,Juan Mo,Xiu‐Jing Zheng,Yi‐Qun Geng,Xin‐Shan Ye
DOI: https://doi.org/10.1002/adhm.202401649
IF: 10
2024-06-23
Advanced Healthcare Materials
Abstract:Immune checkpoint blockade (ICB) has significantly improved the prognosis of patients with cancer, although the majority of such patients achieve low response rates; consequently, new therapeutic approaches are urgently needed. The upregulation of sialic acid‐containing glycans is a common characteristic of cancer‐related glycosylation, which drives disease progression and immune escape via numerous pathways. Herein, we report the development of self‐assembled core‐shell nanoscale coordination polymer nanoparticles loaded with a sialyltransferase inhibitor, referred to as NCP‐STI which effectively stripped diverse sialoglycans from cancer cells, providing an antibody‐independent pattern to disrupt the emerging Siglec‐sialic acid glyco‐immune checkpoint. Furthermore, NCP‐STI inhibited sialylation of the concentrated nucleoside transporter 1 (CNT1), promoted the intracellular accumulation of anticancer agent gemcitabine (Gem), and enhanced Gem‐induced immunogenic cell death (ICD). As a result, the combination of NCP‐STI and Gem (NCP‐STI/Gem) evoked a robust antitumor immune response and exhibited superior efficacy in restraining the growth of multiple murine tumors and pulmonary metastasis. Collectively, our findings demonstrate a novel form of small molecule‐based chemo‐immunotherapy approach which features sialic acids blockade that enables cooperative effects of cancer cell chemosensitivity and antitumor immune responses for cancer treatment. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?